Research-Article

You have full text access to this OnlineOpen article

Growth Hormone Injections Improve Bone Quality in a Mouse Model of Osteogenesis Imperfecta†

  1. Donna King PhD1,*,
  2. David Jarjoura1,‡,
  3. Heather A McEwen1,
  4. Michael J Askew2

Article first published online: 18 JAN 2005

DOI: 10.1359/JBMR.050108

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 20, Issue 6, pages 987–993, June 2005

Additional Information

How to Cite

King, D., Jarjoura, D., McEwen, H. A. and Askew, M. J. (2005), Growth Hormone Injections Improve Bone Quality in a Mouse Model of Osteogenesis Imperfecta. J Bone Miner Res, 20: 987–993. doi: 10.1359/JBMR.050108

Author Information

  1. 1

    Northeastern Ohio Universities College of Medicine, Rootstown, Ohio

  2. 2

    Walter A. Hoyt, Jr. Musculoskeletal Research Laboratory, Summa Health System, Akron Ohio

  1. ‡

    Center for Biostatistics, Ohio State University, Columbus, Ohio

*NEOUCOM, Department of Biochemistry and Molecular Pathology, 4209 State Route 44, Rootstown, OH 44272, USA

  1. †

    The authors have no conflict of interest.

Publication History

  1. Issue published online: 4 DEC 2009
  2. Article first published online: 18 JAN 2005
  3. Manuscript Accepted: 12 JAN 2005
  4. Manuscript Revised: 5 JAN 2005
  5. Manuscript Received: 12 OCT 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (107K)

REFERENCES

  • 1
    Plotkin H 2004 Syndromes with congenital brittle bones. BMC Pediatr 4: 16.
  • 2
    Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP 1993 Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet 45: 261–264.
  • 3
    Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC, Gundberg CM, Reing CM 2003 Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: High predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res 18: 237–243.
  • 4
    Vieira NE, Marini JC, Hopkins E, Abrams SA, Yergey AL 1999 Effect of growth hormone treatment on calcium kinetics in patients with osteogenesis imperfecta type III and IV. Bone 25: 501–505.
  • 5
    Vieira NE, Goans RE, Weiss GH, Hopkins E, Marini JC, Yergey AL 2000 Calcium kinetics in children with osteogenesis imperfecta type III and IV: Pre- and post-growth hormone therapy. Calcif Tissue Int 67: 97–100.
  • 6
    Chipman SD, Sweet HO, McBride DJ Jr, Davisson MT, Marks SC Jr, Shuldiner AR, Wenstrup RJ, Rowe DW, Shapiro JR 1993 Defective pro alpha 2(I) collagen synthesis in a recessive mutation in mice: A model of human osteogenesis imperfecta. Proc Natl Acad Sci USA 90: 1701–1705.
  • 7
    Balk ML, Bray J, Day C, Epperly M, Greenberger J, Evans CH, Niyibizi C 1997 Effect of rhBMP-2 on the osteogenic potential of bone marrow stromal cells from an osteogenesis imperfecta mouse (oim). Bone 21: 7–15.
  • 8
    Camacho NP, Landis WJ, Boskey AL 1996 Mineral changes in a mouse model of osteogenesis imperfecta detected by Fourier transform infrared microscopy. Connect Tissue Res 35: 259–265.
  • 9
    Camacho NP, Hou L, Toledano TR, Ilg WA, Brayton CF, Raggio CL, Root L, Boskey AL 1999 The material basis for reduced mechanical properties in oim mice bones. J Bone Miner Res 14: 264–272.
  • 10
    Grabner B, Landis WJ, Roschger P, Rinnerthaler S, Peterlik H, Klaushofer K, Fratzl P 2001 Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim). Bone 29: 453–457.
  • 11
    Saban J, Zussman MA, Havey R, Patwardhan AG, Schneider GB, King D 1996 Heterozygous oim mice exhibit a mild form of osteogenesis imperfecta. Bone 19: 575–579.
  • 12
    King D, Chase JM, Havey RM, Voronov L, Sartori M, McEwen HA, Beamer WG, Patwardhan AG 2005 Effects of growth hormone transgene expression on vertebrae in a mouse model of osteogenesis imperfecta. Spine (in press)
  • 13
    Vonesh E, Chinchilli V 1977 Linear and Nonlinear Models for the Analysis of Repeated Measurements. Marcel Dekker, New York, NY, USA.
  • 14
    Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, Kolb HJ, Wanke R, Wolf E 2001 Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2. Endocrinology 142: 1889–1898.
  • 15
    Blackburn A, Schmitt A, Schmidt P, Wanke R, Hermanns W, Brem G, Wolf E 1997 Actions and interactions of growth hormone and insulin-like growth factor-II: Body and organ growth of transgenic mice. Transgenic Res 6: 213–222.
  • 16
    Palmiter RD, Norstedt G, Gelinas RE, Hammer RE, Brinster RL 1983 Metallothionein-human GH fusion genes stimulate growth of mice. Science 222: 809–814.
  • 17
    Kasukawa Y, Baylink DJ, Guo R, Mohan S 2003 Evidence that sensitivity to growth hormone (GH) is growth period and tissue type dependent: Studies in GH-deficient lit/lit mice. Endocrinology 144: 3950–3957.
  • 18
    Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A 2001 Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 229: 141–162.
  • 19
    Roach HI, Mehta G, Oreffo ROC, Clarke NMP, Cooper C 2003 Temporal analysis of rat growth plates: Cessation of growth with age despite presence of a physis. J Histochem Cytochem 51: 373–383.
  • 20
    Saban J, King D 1996 PCR genotyping of oim mutant mice. Biotechniques 21: 190–192.
  • 21
    Lund AM, Muller J, Skovby F 1999 Anthropometry of patients with osteogenesis imperfecta. Arch Dis Child 80: 524–528.
  • 22
    Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16: 101–116.
  • 23
    Halvorsen S, Bechensteen AG 2002 Physiology of erythropoietin during mammalian development. Acta Paediatr Suppl 91: 17–26.
  • 24
    Russell ES, Bernstein SE 1966 Blood and blood formation. In: GreenEL (ed.) Biology of the Laboratory Mouse. Dover Publications, New York, NY, USA, pp. 351–372.
  • 25
    Rogers MJ 2003 New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9: 2643–2658.
  • 26
    Bouillon R 1991 Growth hormone and bone. Horm Res 36 (Suppl 1): 49–55.
  • 27
    Sarathchandra P, Cassella JP, Ali SY 2002 Ultrastructural localization of proteoglycans in bone in osteogenesis imperfecta as demonstrated by cuprolinic blue staining. J Bone Miner Metab 20: 288–293.
  • 28
    Vetter U, Fisher LW, Mintz KP, Kopp JB, Tuross N, Termine JD, Robey PG 1991 Osteogenesis imperfecta: Changes in noncollagenous proteins in bone. J Bone Miner Res 6: 501–505.
  • 29
    Traub W, Arad T, Vetter U, Weiner S 1994 Ultrastructural studies of bones from patients with osteogenesis imperfecta. Matrix Biol 14: 337–345.
  • 30
    Rauch F, Travers R, Parfitt AM, Glorieux FH 2000 Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 26: 581–589.
  • 31
    Antoniazzi F, Bertoldo F, Mottes M, Valli M, Sirpresi S, Zamboni G, Valentini R, Tato L 1996 Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 129: 432–439.
  • 32
    Sas TC, Gerver WJ, de Bruin R, Stijnen T, de Muinck Keizer-Schrama SM, Cole TJ, van Teunenbroek A, Drop SL 1999 Body proportions during long-term growth hormone treatment in girls with Turner syndrome participating in a randomized dose-response trial. J Clin Endocrinol Metab 84: 4622–4628.
  • 33
    deGraaf LC, Mulder PG, Hokken-Koelega AC 2003 Body proportions before and during growth hormone therapy in children with chronic renal failure. Pediatr Nephrol 18: 679–684.
  • 34
    Zivicnjak M, Franke D, Ehrich JH, Filler G 2000 Does growth hormone therapy harmonize distorted morphology and body composition in chronic renal failure. Pediatr Nephrol 15: 229–235.
  • 35
    Harris M, Hofman PL, Cutfield WS 2004 Growth hormone treatment in children: Review of safety and efficacy. Paediatr Drugs 6: 93–106.
  • 36
    Cohen P, Bright GM, Rogol AD, Kappelgaard A-M, Rosenfeld RG 2002 Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: Implications for efficacy and safety. J Clin Endocrinol Metab 87: 90–98.
  • 37
    Wyatt D 2004 Lessons from the national cooperative growth study. Eur J Endocrinol 151: S55–S59.
  • 38
    Ogilvy-Stuart AL, Gleeson H 2004 Cancer risk following growth hormone use in childhood: Implications for current practice. Drug Saf 27: 369–382.
View Full Article (HTML) Get PDF (107K)